Jason Cavalier - 06 Jan 2026 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Signature
/s/ Jason Cavalier
Issuer symbol
LYRA
Transactions as of
06 Jan 2026
Net transactions value
-$2,587
Form type
4
Filing time
08 Jan 2026, 16:30:20 UTC
Previous filing
14 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cavalier Jason Chief Financial Officer C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN /s/ Jason Cavalier 08 Jan 2026 0001883290

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYRA Common Stock Sale $2,587 -769 -0.15% $3.36 518,547 06 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.